What Happened?
Boston, MA-based Decibel-Therapeutics Appointed Steven Holtzman as President and Chief Executive Officer
Date of management change: July 15, 2016
Boston, MA-based Decibel-Therapeutics Appointed Steven Holtzman as President and Chief Executive Officer
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.
Steven Holtzman is President and Chief Executive Officer at Decibel Therapeutics. Previously, Steven held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Strack Karen, Ganov Ilya, Ulrich Helen, Kedzior Brian, Batiste Monica, Voisinet Bob, Pazzanese John, Bonsera Cami, McIntosh Jim, Byrne Ryan, Potter Iina
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.